Overview and outcome of mucormycosis among children with cancer: Report from the Children's Cancer Hospital Egypt
Abstract
Summary: Mucormycosis represents a real challenge in immunocompromised patients. This study aimed to describe the clinical characteristics, treatment outcome and infection‐related mortality in our patients at the Children's Cancer Hospital 57357, Cairo, Egypt. This is a retrospective study during the period 2007‐2017. Data analysis included demographic data, risk factors, diagnostic workup, treatment and outcome. During the study period, 45 patients developed proven mucormycosis according to EORTC/MSG criteria (2008). Ninety percentof cases were of haematological malignancies. Liposomal amphotericin B was the mainstay of treatment. Posaconazole was used as secondary prophylaxis in 35% of cases. Combination antifungal was used in three cases with progressive mucormycosis. Surgical intervention was achievable in 50% of cases. Therapy was successful in 35 patients (66%). Complications related to mucormycosis were seen in five cases with disfigurement and perforated hard palate. Chemotherapy delay with subsequent relapse of primary malignancy was reported in one case. Mucormycosis‐related mortality was 33% (15 cases). Mucormycosis is a major cause of mortality among patients with haematological malignancies. Early diagnosis of Mucormycosis infection, with rapid initiation of appropriate antifungal therapy and surgical intervention, whenever feasible, is the backbone of mucormycosis treatment.Keywords
This publication has 22 references indexed in Scilit:
- Early Clinical and Laboratory Diagnosis of Invasive Pulmonary, Extrapulmonary, and Disseminated Mucormycosis (Zygomycosis)Clinical Infectious Diseases, 2012
- Epidemiology and Clinical Manifestations of MucormycosisClinical Infectious Diseases, 2012
- A Global Analysis of Mucormycosis in France: The RetroZygo Study (2005-2007)Clinical Infectious Diseases, 2012
- Zygomycosis in Europe: analysis of 230 cases accrued by the registry of the European Confederation of Medical Mycology (ECMM) Working Group on Zygomycosis between 2005 and 2007Clinical Microbiology and Infection, 2011
- The Diagnostic Value of Halo and Reversed Halo Signs for Invasive Mold Infections in Compromised HostsClinical Infectious Diseases, 2011
- Mucormycosis Caused by Unusual Mucormycetes, Non-Rhizopus, -Mucor, and -Lichtheimia SpeciesClinical Microbiology Reviews, 2011
- Defining Responses to Therapy and Study Outcomes in Clinical Trials of Invasive Fungal Diseases: Mycoses Study Group and European Organization for Research and Treatment of Cancer Consensus CriteriaClinical Infectious Diseases, 2008
- Revised Definitions of Invasive Fungal Disease from the European Organization for Research and Treatment of Cancer/Invasive Fungal Infections Cooperative Group and the National Institute of Allergy and Infectious Diseases Mycoses Study Group (EORTC/MSG) Consensus GroupClinical Infectious Diseases, 2008
- Zygomycosis in Children: A Systematic Review and Analysis of Reported CasesThe Pediatric Infectious Disease Journal, 2007
- Breakthrough fungal infections after allogeneic hematopoietic stem cell transplantation in patients on prophylactic voriconazoleBone Marrow Transplantation, 2007